

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then after surgery (adjuvant) for treating muscle-invasive bladder cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

Stakeholders at scoping raised concerns that women are being diagnosed with muscle-invasive bladder cancer at a later stage than men. Stakeholders also raised equality of access with regards to treatment and that patients in rural areas and smaller hospitals have equal opportunity to access new treatments. It is not anticipated that the recommendation will make it more difficult in practice for a specific group to access the technology

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No.

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then after surgery (adjuvant) for treating muscle-invasive bladder cancer

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Equalities are discussed in section 3.8 of the guidance.

Approved by Associate Director (name): Ross Dent

Date: 19 January 2026

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then after surgery (adjuvant) for treating muscle-invasive bladder cancer